Compare Enveric Biosciences Inc (ENVB) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Prospect Capital Corporation — how do they compare? Enveric Biosciences Inc trades at $1.58 (market cap $6.20M), while Prospect Capital Corporation trades at $2.29 (market cap $1.14B). The key difference: Prospect Capital Corporation is far larger — about 183.9× Enveric Biosciences Inc's market cap, and Prospect Capital Corporation pays a 21.93% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | PSEC | |
|---|---|---|
Market Cap | $6.20M | $1.14B |
Sector | Health | Financials |
52-Week High | $17.40 | $3.05 |
52-Week Low | $1.27 | $2.11 |
Enterprise Value | $1.30M | — |
Dividend Yield | — | 21.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.56, up 1.3% on the day, with a bullish technical signal from moving averages and strong analyst support (75% buy ratings). The company reported four consecutive quarterly earnings beats in 2025, including a positive EPS of $0.85 in Q4, while recent news highlights progress in preclinical studies for its non-hallucinogenic psychiatric drug candidate EB-003.
Despite operational losses and negative ROE/ROA, ENVB's consistent earnings surprises and advancing pipeline present speculative growth potential. Key risks include cash burn, clinical trial outcomes, and regulatory hurdles, requiring careful risk assessment by investors.
PSEC trades at $2.29, down 1.72% on the day, with a mixed technical picture showing a bullish moving average signal but neutral oscillators. The stock carries a low P/B of 0.39 and has beaten earnings estimates for three consecutive quarters, though it reported a net loss of $469.92 million in 2025. Recent news includes a dividend increase announcement and the sale of portfolio company Valley Electric for $328 million.
The outlook is cautious; while the deep discount to book value and consistent dividend payments offer income appeal, significant negative revenue and net income margins, alongside a divided analyst consensus, highlight substantial business and market risks. The primary opportunity lies in a potential valuation recovery if operational performance improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
